National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting, 81554-81555 [2015-32769]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
81554
Federal Register / Vol. 80, No. 250 / Wednesday, December 30, 2015 / Notices
Center Drive, Mail Stop 9702, Rockville,
MD 20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below, may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Title of invention: Thalidomide/
lenolidomide/pomalidomide analogs
that inhibit inflammation, angiogenesis.
Description of Technology:
Thalidomide and its close analogs
(lenalidomide and pomalidomide) are
widely used to treat a variety of
diseases, such as multiple myeloma and
other cancers, as well as the symptoms
of several inflammatory disorders.
However, thalidomide is known for its
teratogenic adverse effects when first
introduced clinically in the 1950s, and
is associated with drowsiness and
peripheral neuropathy. Hence, there is
intense interest to synthesize, identify
and develop safer analogs. Researchers
at the National Institute on Aging’s Drug
Design and Development Section
synthesized novel thalidomide analogs
that demonstrate clinical potential
without being teratogenic, as initially
evaluated in in vivo zebrafish and
chicken embryo model systems and in
cell culture. These new compounds
differentially provide potent antiangiogenesis and/or anti-inflammatory
action. The agents have potential for
development of new cancer therapies
and treatment of a number of
neurological and systemic disorders
involving chronic inflammation and
elevated TNF-alpha levels.
Potential Commercial Applications:
—Cancer therapeutics
—Inflammatory disorders such as
Crohn’s disease, sarcoidosis, graftversus-host disease, and rheumatoid
arthritis
—Neuroinflammatory disorders (acute:
Traumatic brain injury and stroke;
chronic: Parkinson’s disease,
Alzheimer’s disease, multiple
sclerosis)
Value Proposition:
—Non-teratogenic
—Potent
Development Stage:
VerDate Sep<11>2014
17:59 Dec 29, 2015
Jkt 238001
In Vitro/Discovery
Inventor(s):
Nigel H. Greig (NIA), Weiming Luo
(NIA), David Tweedie (NIA), William
Douglas Figg, Sr. (NCI), Neil Vargesson
(Univ. Aberdeen, Scotland), and
Shaunna Beedie (NCI & Univ. Aberdeen,
Scotland)
Intellectual Property:
HHS Reference No. E–208–2015/0–US–
01
U.S. Provisional Patent Application
No. 62/235, 105, filed September 30,
2015, entitled ‘‘Thalidomide/
lenolidomide/pomalidomide analogs
that inhibit inflammation, angiogenesis’’
Licensing and Collaborative/CoDevelopment Research Opportunity:
The National Institute on Aging seeks
collaborators to license or co-develop
novel thalidomide analogs that
demonstrate clinical potential without
being teratogenic.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing and/or
research collaboration and codevelopment opportunities should be
sent to John D. Hewes, Ph.D., email:
john.hewes@nih.gov.
CFR Citation: 35 U.S.C. 209 and 37
CFR part 404
Dated: December 22, 2015.
Thomas M. Stackhouse,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2015–32877 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Rodent
Tissue Bank.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Date: January 29, 2016.
Time: 12:30 p.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute on Aging,
Gateway Building, Suite 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Kimberly Firth, Ph.D.,
National Institutes of Health, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7702 firthkm@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 23, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32772 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director; Amended Notice
of Meeting
Notice is hereby given of a correction
in the meeting notice of the Big Data to
Knowledge Multi-Council Working
Group (BD2K) that was published in the
Federal Register on Friday, December
11, 2015, 80 FRN 76996.
The date of the meeting is January 11,
2016. The time and meeting access
codes remain the same.
A portion of the meeting is open to
the public, 11 a.m. to 12:00 p.m. and is
being held by teleconference only. No
physical meeting location is provided
for any interested individuals to listen
to committee discussions. Any
individual interested in listening to the
meeting discussions must call: 1–866–
692–3158 and use Passcode 2956317 for
access to the meeting.
Dated: December 23, 2015.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32768 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\30DEN1.SGM
30DEN1
Federal Register / Vol. 80, No. 250 / Wednesday, December 30, 2015 / Notices
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; Center for Complex
Tissues (2016/05).
Date: February 15, 2016.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 959, Bethesda, MD 20892,
(301)–451–3398, hayesj@mail.nih.gov.
Dated: December 23, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Time: 10:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room # 3G41B, National Institutes
of Health/NIAID, 5601 Fishers Lane,
MSC9823, Bethesda, MD 20892–9823, (240)
669–5068, zhuqing.li@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Partnerships for the
Development of Host-Targeted Therapeutics
to Limit Antimicrobial Resistance (R01).
Date: January 28–29, 2016.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
2H 200 A/B, 3F100, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Susana Mendez, DVM,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room 3G53B, National Institutes
of Health, NIAID, 5601 Fishers Lane Dr.,
MSC 9823, Bethesda, MD 20892–9823, (240)
669–5077, mendezs@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: December 23, 2015.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32769 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–32766 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Center for Scientific Review; Notice of
Closed Meeting
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: January 28, 2016.
VerDate Sep<11>2014
17:59 Dec 29, 2015
Jkt 238001
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–14–
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
81555
092: Bioengineering Research Partnerships
(BRP).
Date: January 21, 2016.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Mehrdad Mohseni, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5211,
MSC 7854, Bethesda, MD 20892, 301–435–
0484, mohsenim@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 23, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32770 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute, Technology Transfer Center on
or before January 29, 2016 will be
considered.
SUMMARY:
Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD, 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
ADDRESSES:
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 80, Number 250 (Wednesday, December 30, 2015)]
[Notices]
[Pages 81554-81555]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32769]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 81555]]
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Biomedical Imaging and
Bioengineering Special Emphasis Panel; Center for Complex Tissues
(2016/05).
Date: February 15, 2016.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, Suite
920, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: John K. Hayes, Ph.D., Scientific Review Officer,
6707 Democracy Boulevard, Suite 959, Bethesda, MD 20892, (301)-451-
3398, hayesj@mail.nih.gov.
Dated: December 23, 2015.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-32769 Filed 12-29-15; 8:45 am]
BILLING CODE 4140-01-P
